Docs
All documentation Fundamental API Live (Delayed) API EOD Historical API Intraday API Real-Time (websockets) API Google Sheets add-on Excel add-on
Community
Academy 134 articles Forum Github 13 repos
Marketplace
Spreadsheets
Google Sheets add-on Excel add-on Wordpress plugin
Pricing
Overview Fundamentals API Earnings EOD API Sample Code Pricing
Register now
Free trial

No credit cards required

Get free API key
  1. Supported exchanges /
  2. NASDAQ /
  3. NMRA.NASDAQ

Neumora Therapeutics Inc. Common Stock (NMRA NASDAQ) stock market data APIs

$12.73 -0.17(-1.3%) as of July 26, 2024
Price chart is built with Anychart

Neumora Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the treatment of major depressive disorder. It also develops NMRA-511 that is in phase 1 clinical trials in patients with agitation associated with dementia due to Alzheimer's disease; and NMRA-266, which is in the phase 1 clinical trial for the treatment of schizophrenia and other neuropsychiatric disorders. In addition, its preclinical phase product includes NMRA-NMDA for the treatment of schizophrenia; NMRA-CK1d, a CK1d inhibitor program for the treatment of amyotrophic lateral sclerosis; NMRA-NLRP3 for the treatment of certain neurodegenerative conditions; and NMRA-GCase for the treatment of Parkinson's disease. The company was formerly known as RBNC Therapeutics, Inc. and changed its name to Neumora Therapeutics, Inc. in October 2021. Neumora Therapeutics, Inc. was incorporated in 2019 and is headquartered in Watertown, Massachusetts.

Neumora Therapeutics Inc. Common Stock Financial Data Overview

12.9
12.73
-
12.92
12.31
8.33-21
1 614 M
159 M
0
-0.3371
Our easy-to-use no-coding solutions help you get the data effortlessly:
Excel Financial Add-In Google Sheets Financial Add-In Python
APIs SDK Windows Downloader

No long-term obligations. The minimum period is one month only. No wait. You get an API key with instructions in a few seconds right after subscription.

General: {
Code: 'NMRA',
Type: 'Common Stock',
Name: 'Neumora Therapeutics Inc. Common Stock',
Exchange: 'NASDAQ',
CurrencyCode: 'USD',
CurrencyName: 'US Dollar',
CurrencySymbol: '$',
CountryName: 'USA',
CountryISO: 'US',
OpenFigi: 'BBG012W9C4X1',
ISIN: NULL,
CUSIP: NULL,
CIK: '1885522',
EmployerIdNumber: NULL,
FiscalYearEnd: 'December',
IPODate: '2023-09-14',
InternationalDomestic: NULL,
Sector: 'Healthcare',
Industry: 'Biotechnology',
HomeCategory: NULL,
IsDelisted: false,
}

Neumora Therapeutics Inc. Common Stock Fundamental Data is available in our Financial Data APIs

  • Net Revenue 0
  • EBITDA -187 526 000
  • Earnings Per Share -3.63
  • Income Statements
  • Balance Sheets
  • Cash flows
Fundamental data package from $59.99 See full price
Get sample
of Fundamental API Data

Get Neumora Therapeutics Inc. Common Stock Earnings via APIs

  • Latest Release 2024-05-07
  • EPS/Forecast NaN

Get Neumora Therapeutics Inc. Common Stock End-of-day Data via APIs

  • End of Day, Intraday and Live APIs
  • Splits
  • Dividends

Get Neumora Therapeutics Inc. Common Stock latest news via APIs

Neumora Therapeutics Announces Initiation of Phase 1b Study of NMRA-511 for Treatment of Alzheimer’s Disease Agitation

Neumora Therapeutics, Inc. NMRA-511 is a highly potent and selective, best-in-class, antagonist of the vasopressin 1a receptor, which is known to play a role in regulation of aggression, stress and a...

This Neumora Therapeutics Insider Increased Their Holding In The Last Year

Insiders were net buyers of Neumora Therapeutics, Inc.'s (NASDAQ:NMRA ) stock during the past year. That is, insiders bought more stock than they sold. While insider transactions are not the most imp...
Do you have any questions?
support@eodhistoricaldata.com